TALENTop: A multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment.

医学 阿替唑单抗 临床终点 肝细胞癌 肿瘤科 贝伐单抗 内科学 随机对照试验 外科 癌症 化疗 无容量 免疫疗法
作者
Hui–Chuan Sun,Feng Shen,Lianxin Liu,Zhiyong Huang,Tianqiang Song,Ming Kuang,Bang‐De Xiang,Xiangzhi Bai,Xiaodong Zhu,Jian Zhou,Jun Fan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): TPS4175-TPS4175 被引量:2
标识
DOI:10.1200/jco.2022.40.16_suppl.tps4175
摘要

TPS4175 Background: Hepatocellular carcinoma (HCC) patients with macrovascular invasion are consistently considered to be at an advanced stage of disease. The combination therapy of atezolizumab (atezo) plus bevacizumab (bev) has been the new standard-of-care for those patients. In patients responding to systemic therapy, hepatic resection may provide additional benefit. Here we propose a phase 3 study to investigate whether hepatic resection following atezo/bev can bring more benefits for HCC patients with macrovascular invasion when compared with atezo/bev alone. Methods: This is a multicenter, open-label, two-arm, randomized study designed to evaluate the efficacy and safety of surgical resection plus peri-operative atezo/bev compared with regular systemic atezo/bev (Q3W, every three weeks) in HCC patients with macrovascular invasion and without extrahepatic metastasis. Initially eligible patients have enrolled into induction phase, during which they receive 3 cycles of atezo/bev and 1 cycle of atezo alone as primary systemic therapy. Patients who are assessed as partial response or stable disease (RECIST v1.1 criteria) and considered suitable for R0 hepatic resection are randomized in a 1:1 ratio to either Arm A, hepatic resection with post-operative atezo/bev for 1 year (or until loss of clinical benefit or intolerable toxic effects), or Arm B, continuing atezo/bev for 1 year (or until loss of clinical benefit or intolerable toxic effects). The primary endpoint of this study is time-to treatment failure (TTF), defined as time from randomization to the first documented treatment failure (i.e., tumor recurrence or metastasis [Arm A], disease progression [Arm B] according to RECIST v1.1, or death from any cause). We hypothesize that hepatic surgery with peri-operative atezo/bev will improve the TTF from 5.8 months to 9.2 months, with the hazard ratio of 0.63. With 2-sided significance level of 0.05, the sample size for randomization will be 198. The study, registered with clinical trial ID of NCT04649489, started enrollment in Apr 2021. As of Jan 2022, 65 patients have been enrolled and 15 patients have been randomized. Research funding: Shanghai Roche Pharmaceuticals Ltd. Clinical trial information: NCT04649489.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
神经蛙发布了新的文献求助10
1秒前
达不溜完成签到,获得积分10
1秒前
69岁扶墙上班完成签到 ,获得积分10
1秒前
1秒前
susong987完成签到,获得积分0
1秒前
1秒前
1秒前
李爱国的应助被mlg1552003采纳,获得10
2秒前
HJJHJH发布了新的文献求助10
2秒前
Young发布了新的文献求助20
2秒前
纯真的安萱完成签到 ,获得积分10
3秒前
pl完成签到,获得积分10
3秒前
风格化橙发布了新的文献求助10
3秒前
子时月完成签到,获得积分20
3秒前
李爱国的应助被abc37采纳,获得10
3秒前
kl完成签到 ,获得积分10
3秒前
嘻嘻哈哈的应助被hana采纳,获得10
4秒前
汉堡包的应助被二马三乡采纳,获得10
4秒前
4秒前
5秒前
顾矜的应助被伶俐的灵珊采纳,获得10
5秒前
搜集达人的应助被唐唐采纳,获得10
5秒前
11122发布了新的文献求助10
5秒前
Ending完成签到,获得积分10
5秒前
CLOUD发布了新的文献求助10
5秒前
5秒前
碎觉觉发布了新的文献求助10
5秒前
yin完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
搜集达人的应助被专注以筠采纳,获得10
6秒前
球球帮我找找文献完成签到,获得积分10
6秒前
健忘绮南给健忘绮南的求助进行了留言
6秒前
合适南霜发布了新的文献求助10
6秒前
嘟嘟完成签到,获得积分10
7秒前
SibetHu发布了新的文献求助10
7秒前
ZUOSG发布了新的文献求助10
7秒前
Lucas的应助被科研通管家采纳,获得10
7秒前
子时月发布了新的文献求助20
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175943
求助须知:如何正确求助?哪些是违规求助? 9567501
关于积分的说明 21793186
捐赠科研通 7770490
什么是DOI,文献DOI怎么找? 3431935
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477485